CONSULTANT HAEMATOLOGIST
A/Prof Kylie Mason
MBBS PhD FRACP FRCPA
After graduating from Medicine at the University of Melbourne, Associate Professor Kylie Mason undertook specialist haematology training in Melbourne and is a fellow of both the Royal Australian College of Physicians (FRACP) and the Royal College of Pathologists of Australia (FRCPA).
Kylie was inspired to complete a Ph.D. at the Walter and Eliza Hall Institute of Medical Research/University of Melbourne focusing on new drugs for leukaemia and lymphoma and the biology of platelets. She has continued research through the University of Melbourne and Peter MacCallum departments of Medicine.
Her work has been published in prestigious international journals and recognized by awards including the Premiers Award for Medical Research and the L’Oreal for Women in Science Award.
Kylie has an appointment as a Clinical Haematologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre and currently cares for patients with all aspects of both benign classical (non-malignant) and malignant haematological disorders. In particular, her main interests are classical haematology, haemoglobinopathies, disorders of Iron metabolism and blood clotting / platelets, Leukaemia (including CLL / CML) and Lymphoma.
Practice Interests
Kylie has an interest in classical haematology, disorders of Iron metabolism and blood clotting / platelets, Leukaemia (including CLL / CML ) and Lymphoma.
Research & Clinical Trials
Kylie has an active interest in clinical trials and in particular translational research relating to her dual role as a clinician and scientist. These include both phase II and phase III clinical trials in leukaemia and lymphoma. Kylie is also actively involved in clinical trial development through the ALLG.
Practice Locations
Currently Kylie sees and treats patients at the Royal Melbourne Hospital private consulting rooms, Parkville.
Kylie is happy to see patients via telehealth or phone consultation if suitable to reduce travel and inconvenience for those who might find it more difficult to get to Parkville.
Being part of the larger Royal Melbourne Hospital and Peter MacCallum Cancer Centre Network enables patients to access the latest in clinical trials or treatments, and investigations as required.
Suite 11, Level 3,
Private Medical Centre
The Royal Melbourne Hospital
Royal Parade
Parkville VIC 3050
Tel: 03 9342 7789 | Fax: 03 9342 8500
Hospital Accreditation
Clinical Interests Include:
Updated May 2025
Extended Profile
A/Prof Kylie Mason
– Key Research, Journal & Book Publications, Presentations &/or Awards
Qualifications
2019 Clinical Associate Professor, Sir Peter MacCallum Department of Oncology, Uni of Melb
2018 – 2021 Senior research fellow, University of Sydney
2013 Research fellow University of Melbourne
2009 Specialist Certificate in Clinical Research (Oncology) First Class Honours, The University of Melbourne
2007 PhD: Medical Biology. (Uni of Melb, WEHI)
2004 Fellow – Royal Australasian College of Physicians
2004 Fellow – Royal College of Pathologists of Australasia
1996 Bachelor of Medicine and Bachelor of Surgery
Awards
2015 RMH Research Medal – Winner
2014 RMH Research Medal – Highly commended
2012 L’Oreal Australia For Women In Science Fellowship – Winner
2011 L’Oreal Australia For Women In Science Fellowship – Highly commended
2009 Named in ‘Melbourne’s Top 100 Most Influential People’ – The Age
2009 Premier’s Award for Health and Medical Research, Victorian State Government
2008 Young Tall Poppy Science Award, Victorian State Government
2007 Student Seminar prize, Walter & Eliza Hall Institute of Medical Research
2006 Cleveland Young Investigator’s Award, Royal Melbourne Hospital
2006 Albert Baikie Memorial Medal – Haematology Society Australia & New Zealand
Professional & Society Memberships
2022 Inaugural Chair anticoagulation stewardship committee Royal Melbourne Hospital
2022 Inaugural Chair anticoagulation stewardship committee Peter MacCallum Cancer Centre
2019 Member Pharmaceutical Benefits Advisory Committee
2019 Member Therapeutic Administration Specialist Advisory Committee on Medicines
2019 Medical Services Advisory Committee – recurrent guest member
2017 Member Pharmaceutical Benefits Advisory Committee Economics Subcommittee
2016 Melbourne Health Human research Ethics Committee
2010 Australian Leukaemia Lymphoma Group
2004 American Society of Hematology
2001 Haematology Society of Australia and New Zealand
Selected Journal Publications – Top 10 (All original studies)
- I Goncalves, C Lewis, B Grainger, R Dring, N Lee, SR Pasricha, J Szer, KD Mason Thrombosis in Patients with Immune Thrombocytopenia: Incidence, Risk and Clinical Outcomes. Research and Practice in Thrombosis and Haemostasis. 2024. 8/2/24.
- Zoe McQuilten, Stephane Heritier, Lucy Fox, Vanessa Fox, Lauren Young, Piers Blombery, Ilona Cunningham, Jennifer Curnow, Alisa Higgins, Devendra K Hiwase, Robin Filshie, Frank Firkin, Paul Lacaze, Kylie Mason, Anthony K Mills, Dominic Pepperell, Sushrut Patil, William Stevenson, Jeff Szer, Neil Waters, Kate Wilson, Stephen Ting, Erica Wood. Protocol: Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open. 2024. 14(5)
- Zoe McQuilten, Stephane Heritier, Lucy Fox, Vanessa Fox, Lauren Young, Piers Blombery, Ilona Cunningham, Jennifer Curnow, Alisa Higgins, Devendra K Hiwase, Robin Filshie, Frank Firkin, Paul Lacaze, Kylie Mason, Anthony K Mills, Dominic Pepperell, Sushrut Patil, William Stevenson, Jeff Szer, Neil Waters, Kate Wilson, Stephen Ting, Erica Wood. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open. 2024 14(1)
- Anna Nelson, P Joy Ho, Helen Haysom, Neil Waters, Cameron Wellard, Melissa Chee, Juliana Teo, Anthea Greenway, Kylie Mason, Giselle Kidson‐Gerber, Zane Kaplan, Tina Carter, Merrole F Cole‐Sinclair, Pasquale Barbaro, Erica M Wood. Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry. Haemoglobinopathy Registry investigators. Internal Medicine Journal. 2023 12/8 (1-9)
- Jacoline EC Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein WM van der Poel, Wendy BC Stevens, Josee M Zijlstra, Dieta Brandsma, Marcel Nijland, Kylie D Mason, Aart Beeker, Martine CJ Abrahamse-Testroote, Martin J van den Bent, Daphne de Jong, Jeanette K Doorduijn. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro-Oncology. 2023. 12/1. Noad224.
- Mary Xu, Arian Lasocki, Mathias Bressel, Natalie Goroncy, Greg Wheeler, Mary Dwyer, Kirsty Wiltshire, John F Seymour, Neda Haghighi, Kylie Mason, Damien Tange, Belinda A Campbell. Favourable outcomes with an initial active surveillance strategy for asymptomatic radiation-induced meningiomas in long-term survivors of paediatric and young adult malignancies. Radiotherapy and Oncology. 2023. 189 (109916)
- P1156: in the absence of symptoms or cerebrospinal fluid involvement, MRI staging of the central nervous system (CNS) in patients with systemic diffuse large b-cell lymphoma Manu Juneja, Rory Bennett, Mary Ann Anderson, Adrian Minson, Max Wolf, Kirsten Herbert, Graham J Lieschke, Andrew Roberts, Kylie Mason, John Seymour, Michael Dickinson. 2023 Hemasphere. 7(S3) e36667c1
- Pietro R Di Ciaccio, Georgia Mills, Michael J Shipton, Belinda Campbell, Gareth Gregory, Jenna Langfield, Matthew Greenwood, Sean McKeague, Mohammad Shanavas, Renee Eslick, Giselle Kidson‐Gerber, Portia Smallbone, Catherine Tang, Kirk Morris, Ian Bilmon, Costas K Yannakou, Xavier Badoux, Leanne Berkahn, Sergio Farina, Kylie D Mason, Penelope Motum, Kathryn Goss, Nada Hamad. The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance. British Journal of Haematology. 2021(5) 887-896
- Georgia S Mills, Pietro R Di Ciaccio, Catherine Tang, Verity Chadwick, Kylie D Mason, Belinda A Campbell, Michael J Shipton, Mohamed Shanavas, Kirk L Morris, Matthew Greenwood, Jenna Langfield, Giselle Kidson-Gerber, Renee Eslick, Xavier Badoux, Costas K Yannakou, Shane A Gangatharan, Ian Bilmon, Nada Hamad. Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study. Leukaemia & Lymphoma 2022,11, pg1-10
- Zoe McQuilten, Lucy C Fox, Vanessa Fox, Stephane Heritier, Tracey J Batt, Piers Blombery, Jennifer Curnow, Alisa Higgins, Devendra Hiwase, Robin J Filshie, Frank Firkin, Paul Lacaze, Kylie D Mason, Tony Mills, Sushrut S Patil, Dominic Pepperell, William S Stevenson, Jeffrey Szer, Neil Waters, Kate Wilson, Stephen B Ting, Erica M Wood. Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia-the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials. Blood. 2022. 140 S1 p2931-2932
- James E. Vince, W. Wei-Lynn Wong, Ian Gentle, Ramanjaneyulu Allam, Lorraine O’Reilly, Kylie D Mason, Olaf Gross, Greta Guarda, Rosa Castillo, Georg Hacker, John Silke and Jurg Tschopp. Inhibitor of apoptosis (IAP) proteins regulate IL-1 activation. Immunity 2012, 36 (2), 215-227 (impact factor 24.22)
- Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie D, Grigg AP, Seymour JF, Szer J, Huang DCS, Roberts AW; The BH3 mimetic compound ABT-737 Synergizes with a Range of Cytotoxic Chemotherapy Agents in Chronic Lymphocytic Leukemia. Leukemia, 2009; 23(11): 2034-41
- Kylie D. Mason, Cassandra J. Vandenberg, Clare L. Scott, Andrew H. Wei, Suzanne Cory, David C.S. Huang, Andrew Roberts; In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. PNAS 2008; 105(46): 17961-6.
- Mason KD, Juneja SK; Go with the flow for monitoring response in myeloma patients with minimal residual disease. Leukemia and Lymphoma, Feb 2008; 49(2): 117-8.
- Mason KD, Juneja SK; The value and limitations of immunophenotyping in Acute Myeloid Leukaemia. Educational supplement RCPA Quality Assurance Program. May 2007
- Mason KD, Carpinelli M, Fletcher J, Collinge J, Hilton A, Ellis S, Kelly P, Ekert P, Metcalf D, Roberts AW, Huang DCS, Kile BT ; Programmed anuclear cell death delimits platelet life span. Cell, 2007; 128, 1173-1186. Cited as ‘Exceptional’ by Faculties of 1000 in Medicine and Biology.
- van Delft M, Wei A, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis S, Scott CL, Day C, Cory S, Adams J, Roberts AW, Huang DCS; The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006; 10 (5) 389-399. Cited as ‘Must Read’ by Faculties of 1000 in Biology.
- Mason KD, Juneja SJ, Szer J; The immunophenotype of Acute Myeloid Leukaemia: Is there a relationship to prognosis? Blood Reviews, 2006 (20) 71-82.
- Mason KD, Szer J; Investigating patients with Macrocytosis. Medicine Today, 2005 6(12) 35-39.
- Mason KD, Juneja S; Spontaneous rupture of the spleen in the blastic variant of mantle cell lymphoma. Journal of Clinical and Laboratory Haematology, 2003, 25(4), 263-265., Deidun D, Hynes K, Monagle P. Alopecia and dalteparin: a previously unreported association. Blood. 2000;96(4):1618-9.
